Drug: Arzerra

ARZERRA (ofatumumab) is an IgG1K human monoclonal antibody with a molecular weight of approximately 149 kDa. The antibody was generated via transgenic mouse and hybridoma technology and is produced in a recombinant murine cell line (NS0) using standard mammalian cell cultivation and purification technologies. ARZERRA is a sterile, clear to opalescent, colorless, preservative-free liquid concentrate for intravenous administration. ARZERRA is supplied at a concentration of 20 mg/mL in single-use vials. Each single-use vial contains either 100 mg ofatumumab in 5 mL of solution or 1,000 mg ofatumumab in 50 mL of solution. Inactive ingredients include: 10 mg/mL arginine, diluted hydrochloric acid, 0.019 mg/mL edentate disodium, 0.2 mg/mL polysorbate 80, 6.8 mg/mL sodium acetate, 2.98 mg/mL sodium chloride, and Water for Injection, USP. The pH is 5.5.

Source: http://www.rxlist.com

The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
  • Infusion Reactions [see WARNINGS AND PRECAUTIONS]
  • Hepatitis B Virus Reactivation [see WARNINGS AND PRECAUTIONS]
  • Hepatitis B Virus Infection [see WARNINGS AND PRECAUTIONS]
  • Progressive Multifocal Leukoencephalopathy [see WARNINGS AND PRECAUTIONS]
  • Tumor Lysis Syndrome [see WARNINGS AND PRECAUTIONS]
  • Cytopenias [see WARNINGS AND PRECAUTIONS]
Previously Untreated CLL The most common adverse reactions ( ≥ 10%) were infusion reactions and neutropenia (Table 3). Refractory CLL The most common adverse reactions ( ≥ 10%) were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections (Table 5). The most common serious adverse reactions were infections (including pneumonia and sepsis), neutropenia, and pyrexia. Infections were the most common adverse reactions leading to drug discontinuation. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Previously Untreated CLL The safety of ARZERRA was evaluated in an open-label, parallelarm, randomized trial (Study 1) in 444 patients with previously untreated CLL. Patients were randomized to receive either ARZERRA as an intravenous infusion every 28 days in combination with chlorambucil (n = 217) or chlorambucil as a single agent (n = 227). In both arms, patients received chlorambucil 10 mg/m orally on Days 1 to 7 every 28 days. The infusion schedule for ARZERRA was 300 mg administered on Cycle 1 Day 1, 1,000 mg administered on Cycle 1 Day 8, and 1,000 mg administered on Day 1 of subsequent 28-day cycles. The median number of cycles of ARZERRA completed was 6. The data described in Table 3 include relevant adverse reactions occurring up to 60 days after the last dose of study medication; Table 4 includes relevant hematologic laboratory abnormalities. Table 3: Adverse Reactions With ≥ 5% Incidence in Patients Receiving ARZERRA Plus Chlorambucil and Also ≥ 2% More Than Patients Receiving Chlorambucil
Adverse Reactions ARZERRA Plus Chlorambucil (N = 217) Chlorambucil (N = 227) All Grades
% Grade ≥ 3
% All Grades
% Grade ≥ 3
% Infusion reactionsa 67 10 0 0 Neutropenia 27 26 18 14 Asthenia 8 < 1 5 0 Headache 7 < 1 3 0 Leukopenia 6 3 2 < 1 Herpes simplexb 6 0 4 < 1 Lower respiratory tract infection 5 1 3 < 1 Arthralgia 5 < 1 3 0 Upper abdominal pain 5 0 3 0 a Includes events which occurred on the day of an infusion or within 24 hours of the end of an infusion and resulted in an interruption or discontinuation of treatment. Infusion reactions may include, but are not limited to, chills, dyspnea, flushing, hypotension, nausea, pain, pruritus, pyrexia, rash, and urticaria.
b Includes oral herpes, herpes, herpes virus infection, genital herpes, and herpes simplex. Table 4: Post-baseline Hematologic Laboratory Abnormalities Occurring With ≥ 5% Incidence in Patients Receiving ARZERRA Plus Chlorambucil and Also ≥ 2% More Than Patients Receiving Chlorambucil
ARZERRA plus Chlorambucil
(N = 217) Chlorambucil
(N = 227) All Grades
% Grade ≥ 3
% All Grades
% Grade ≥ 3
% Leukopenia 67 23 28 4 Neutropenia 66 29 56 24 Lymphopenia 52 29 20 7 Infusion Reactions Overall, 67% of patients who received ARZERRA in combination with chlorambucil experienced one or more symptoms of infusion reactions (10% were Grade 3 or greater; none were fatal). Infusion reactions that were either Grade 3 or greater, serious, or led to treatment interruption or discontinuation occurred most frequently during Cycle 1 (56% on Day 1 [6% were Grade 3 or greater] and 23% on Day 8 [3% were Grade 3 or greater]) and decreased with subsequent infusions. Infusion reactions led to discontinuation of treatment in 3% of patients. Serious adverse events of infusion reactions occurred in 2% of patients. Neutropenia Overall, 3% of patients had neutropenia as a serious adverse event, reported up to 60 days after the last dose. One patient died with neutropenic sepsis and agranulocytosis. Prolonged neutropenia occurred in 6% of patients receiving ARZERRA in combination with chlorambucil compared with 4% of patients receiving chlorambucil. Late-onset neutropenia occurred in 6% of patients receiving ARZERRA in combination with chlorambucil compared with 1% of patients receiving chlorambucil alone. Refractory CLL The safety of monotherapy with ARZERRA was evaluated in 181 patients with relapsed or refractory CLL in 2 open-label, non-randomized, single-arm studies. In these studies, ARZERRA was administered at 2,000 mg beginning with the second dose for 11 doses (Study 2 [n = 154]) or 3 doses (Study 3 [n = 27]). The data described in Table 5 and other sections below are derived from 154 patients in Study 2. All patients received 2,000 mg weekly from the second dose onward. Ninety percent of patients received at least 8 infusions of ARZERRA and 55% received all 12 infusions. The median age was 63 years (range: 41 to 86 years), 72% were male, and 97% were white. Table 5: Incidence of All Adverse Reactions Occurring in ≥ 5% of Patients and in the Fludarabine- and Alemtuzumab-refractory Subset
Total Population
(N =154) Fludarabine- and Alemtuzumab- refractory
(N =59) Adverse Reaction All Grades
% Grade ≥ 3
% All Grades
% Grade ≥ 3
% Pneumoniaa 23 14 25 15 Pyrexia 20 3 25 5 Cough 19 0 19 0 Diarrhea 18 0 19 0 Anemia 16 5 17 8 Fatigue 15 0 15 0 Dyspnea 14 2 19 5 Rashb 14 < 1 17 2 Bronchitis 11 < 1 19 2 Nausea 11 0 12 0 Upper respiratory tract infection 11 0 3 0 Edema peripheral 9 < 1 8 2 Back pain 8 1 12 2 Chills 8 0 10 0 Nasopharyngitis 8 0 8 0 Sepsisc 8 8 10 10 Urticaria 8 0 5 0 Insomnia 7 0 10 0 Headache 6 0 7 0 Herpes zoster 6 1 7 2 Hyperhidrosis 5 0 5 0 Hypertension 5 0 8 0 Hypotension 5 0 3 0 Muscle spasms 5 0 3 0 Sinusitis 5 2 3 2 Tachycardia 5 < 1 7 2 a Includes pneumonia, lung infection, lobar pneumonia, and bronchopneumonia.
b Includes rash, rash macular, and rash vesicular.
c Includes sepsis, neutropenic sepsis, bacteremia, and septic shock. Infusion Reactions Infusion reactions occurred in 44% of patients on the day of the first infusion (300 mg), 29% on the day of the second infusion (2,000 mg), and less frequently during subsequent infusions. Infections A total of 108 patients (70%) experienced bacterial, viral, or fungal infections. A total of 45 patients (29%) experienced Grade 3 or greater infections, of which 19 (12%) were fatal. The proportion of fatal infections in the fludarabine- and alemtuzumab-refractory group was 17%. Neutropenia Of 108 patients with normal neutrophil counts at baseline, 45 (42%) developed Grade 3 or greater neutropenia. Nineteen (18%) developed Grade 4 neutropenia. Some patients experienced new onset Grade 4 neutropenia > 2 weeks in duration. Immunogenicity There is a potential for immunogenicity with therapeutic proteins such as ofatumumab. Serum samples from more than 300 patients with CLL were tested during and after treatment for antibodies to ARZERRA. There was no formation of anti-ofatumumab antibodies in patients with CLL after treatment with ofatumumab. Immunogenicity assay results are highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to ARZERRA with the incidence of antibodies to other products may be misleading. Postmarketing Experience The following adverse reactions have been identified during post-approval use of ARZERRA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Infusion-related Cardiac Events: Cardiac arrest. Mucocutaneous Reactions: Stevens-Johnson syndrome, porphyria cutanea tarda. Read the Arzerra (ofatumumab injection) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

Recommended Dosage Regimen
  • Dilute and administer as an intravenous infusion according to the following schedules.
  • Do not administer as an intravenous push or bolus or as a subcutaneous injection.
  • Premedicate before each infusion [see Premedication].
Previously Untreated CLL The recommended dosage and schedule is:
  • 300 mg on Day 1 followed 1 week later by 1,000 mg on Day 8 (Cycle 1) followed by
  • 1,000 mg on Day 1 of subsequent 28-day cycles for a minimum of 3 cycles until best response or a maximum of 12 cycles.
Refractory CLL The recommended dosage and schedule is 12 doses administered as follows:
  • 300 mg initial dose (Dose 1), followed 1 week later by
  • 2,000 mg weekly for 7 doses (Doses 2 through 8), followed 4 weeks later by
  • 2,000 mg every 4 weeks for 4 doses (Doses 9 through 12).
Administration Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion reactions are available [see WARNINGS AND PRECAUTIONS]. Prepare all doses in 1,000 mL of 0.9% Sodium Chloride Injection, USP [see Preparation and Administration]. Previously Untreated CLL
  • Cycle 1, Day 1 (300-mg dose): Initiate infusion at a rate of 3.6 mg/hour (12 mL/hour).
  • Cycle 1, Day 8 and Cycles 2 through 12 (1,000-mg doses): Initiate infusion at a rate of 25 mg/hour (25 mL/hour). Initiate infusion at a rate of 12 mg/hour if a Grade 3 or greater infusion-related adverse event was experienced during the previous infusion.
In the absence of an infusion-related adverse event, the rate of infusion may be increased every 30 minutes (Table 1). Do not exceed the infusion rates in Table 1. Table 1: Infusion Rates for ARZERRA in Previously Untreated CLL
Interval After Start of Infusion (min) Cycle 1, Day 1a (mL/hour) Cycle 1, Day 8b and Cycles 2-12c (mL/hour) 0-30 12 25 31-60 25 50 61-90 50 100 91-120 100 200 121-150 200 400 151-180 300 400 > 180 400 400 aCycle 1, Day 1 = 300 mg; median duration of infusion = 5.2 hours.
bCycle 1, Day 8 = 1,000 mg; median duration of infusion = 4.4 hours.
cCycles 2 through 12 = 1,000 mg; median durations of infusion = 4.2 to 4.4 hours. Refractory CLL
  • Dose 1 (300-mg dose): Initiate infusion at a rate of 3.6 mg/hour (12 mL/hour).
  • Dose 2 (2,000-mg dose): Initiate infusion at a rate of 24 mg/hour (12 mL/hour).
  • Doses 3 through 12 (2,000-mg doses): Initiate infusion at a rate of 50 mg/hour (25 mL/hour).
In the absence of an infusion-related adverse event, the rate of infusion may be increased every 30 minutes (Table 2). Do not exceed the infusion rates in Table 2. Table 2: Infusion Rates for ARZERRA in Refractory CLL
Interval After Start of Infusion (min) Dose 1a (mL/hour) Dose 2b (mL/hour) Doses 3-12b (mL/hour) 0-30 12 12 25 31-60 25 25 50 61-90 50 50 100 91-120 100 100 200 > 120 200 200 400 a Dose 1 = 300 mg; median duration of infusion = 6.8 hours.
b Doses 2 and 3 through 12 = 2,000 mg; median duration of infusion for Dose 2 = 6.8 hours; median durations of infusion for Doses 3 through 12 = 4.2 to 4.4 hours. Infusion Rate Dose Modification For Infusion Reactions
  • Interrupt infusion for infusion reactions of any severity [see WARNINGS AND PRECAUTIONS]. Treatment can be resumed at the discretion of the treating physician. The following infusion rate modifications can be used as a guide.
  • If the infusion reaction resolves or remains less than or equal to Grade 2, resume infusion with the following modifications according to the initial Grade of the infusion reaction.
    • Grade 1 or 2: Infuse at one-half of the previous infusion rate.
    • Grade 3 or 4: Infuse at a rate of 12 mL/hour.
  • After resuming the infusion, the infusion rate may be increased according to Tables 1 and 2 above, based on patient tolerance.
  • Consider permanent discontinuation of ARZERRA if the severity of the infusion reaction does not resolve to less than or equal to Grade 2 despite adequate clinical intervention.
  • Permanently discontinue therapy for patients who develop an anaphylactic reaction to ARZERRA.
Premedication Patients should receive the following premedication 30 minutes to 2 hours prior to each infusion of ARZERRA: Previously Untreated CLL
  • Oral acetaminophen 1,000 mg (or equivalent) plus
  • Oral or intravenous antihistamine (diphenhydramine 50 mg or cetirizine 10 mg or equivalent) plus
  • Intravenous corticosteroid (prednisolone 50 mg or equivalent).
If the patient did not experience a Grade 3 or greater infusion-related adverse event during the first 2 infusions of ARZERRA, the dose of corticosteroid may be reduced or omitted for subsequent infusions. Refractory CLL
  • Oral acetaminophen 1,000 mg (or equivalent) plus
  • Oral or intravenous antihistamine (diphenhydramine 50 mg or cetirizine 10 mg or equivalent) 101 plus
  • Intravenous corticosteroid (prednisolone 100 mg or equivalent).
Do not reduce corticosteroid dose for Doses 1, 2, and 9. Corticosteroid dose may be reduced as 105 follows:
  • Doses 3 through 8: Corticosteroid may be reduced or omitted with subsequent infusions if a Grade 3 or greater infusion reaction did not occur with the preceding dose.
  • Doses 10 through 12: Administer prednisolone 50 mg to 100 mg or equivalent if a Grade 3 or greater infusion reaction did not occur with Dose 9.
Preparation And Administration
  • Do not shake product.
  • Inspect parenteral drug products visually for particulate matter and discoloration prior to administration. ARZERRA should be a clear to opalescent, colorless solution. The solution should not be used if discolored or cloudy, or if foreign particulate matter is present.
Preparation of Solution
  • 300-mg dose: Withdraw and discard 15 mL from a 1,000-mL bag of 0.9% Sodium Chloride Injection, USP. Withdraw 5 mL from each of 3 single-use 100-mg vials of ARZERRA and add to the bag. Mix diluted solution by gentle inversion.
  • 1,000-mg dose: Withdraw and discard 50 mL from a 1,000-mL bag of 0.9% Sodium Chloride Injection, USP. Withdraw 50 mL from 1 single-use 1,000-mg vial of ARZERRA and add to the bag. Mix diluted solution by gentle inversion.
  • 2,000-mg dose: Withdraw and discard 100 mL from a 1,000-mL bag of 0.9% Sodium Chloride Injection, USP. Withdraw 50 mL from each of 2 single-use 1,000-mg vials of 126 ARZERRA and add to the bag. Mix diluted solution by gentle inversion.
  • Store diluted solution between 2° to 8°C (36° to 46°F).
  • No incompatibilities between ARZERRA and polyvinylchloride or polyolefin bags and administration sets have been observed.
Administration Instructions
  • Do not mix ARZERRA with, or administer as an infusion with, other medicinal products.
  • Administer using an infusion pump and an administration set.
  • Flush the intravenous line with 0.9% Sodium Chloride Injection, USP before and after each dose.
  • Start infusion within 12 hours of preparation.
  • Discard prepared solution after 24 hours.

Source: http://www.rxlist.com

Coadministration of ARZERRA with chlorambucil did not result in clinically relevant effects on the pharmacokinetics of chlorambucil or its active metabolite, phenylacetic acid mustard. Read the Arzerra Drug Interactions Center for a complete guide to possible interactions Learn More »

Source: http://www.rxlist.com

Previously Untreated Chronic Lymphocytic Leukemia ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabinebased therapy is considered inappropriate [see Clinical Studies]. Refractory CLL ARZERRA is indicated for the treatment of patients with CLL refractory to fludarabine and alemtuzumab [see Clinical Studies].

Source: http://www.rxlist.com

None. Last reviewed on RxList: 4/30/2014
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

No data are available regarding overdosage with ARZERRA.

Source: http://www.rxlist.com

Dosage Forms And Strengths
  • 100 mg/5 mL single-use vial for intravenous infusion.
  • 1,000 mg/50 mL single-use vial for intravenous infusion.
Storage And Handling ARZERRA (ofatumumab) is a sterile, clear to opalescent, colorless, preservative-free liquid concentrate (20 mg/mL) for dilution and intravenous administration provided in single-use glass vials with a rubber stopper (not made with natural rubber latex) and an aluminum overseal. Each vial contains either 100 mg ofatumumab in 5 mL of solution or 1,000 mg ofatumumab in 50 mL of solution. ARZERRA is available as follows: Carton Contents NDC 3 single-use 100 mg/5 mL vials Vial: NDC 0173-0821-02 Carton of 3 vials: NDC 0173-0821-33 1 single-use 1,000 mg/50 mL vial Vial and Carton: NDC 0173-0821-01 Store ARZERRA refrigerated between 2° to 8°C (36° to 46°F). Do not freeze. Vials should be protected from light. Manufactured by: Glaxo Group Limited, Brentford, Middlesex, TW8 9GS, United Kingdom. Distributed by: GlaxoSmithKline, Research Triangle Park, NC 27709. Revised: Apr 2014 Last reviewed on RxList: 4/30/2014
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Infusion Reactions ARZERRA can cause serious, including fatal, infusion reactions manifesting as bronchospasm, dyspnea, laryngeal edema, pulmonary edema, flushing, hypertension, hypotension, syncope, cardiac events (e.g., myocardial ischemia/infarction, acute coronary syndrome, arrhythmia, bradycardia), back pain, abdominal pain, pyrexia, rash, urticaria, angioedema, cytokine release syndrome, and anaphylactoid/anaphylactic reactions. Infusion reactions occur more frequently with the first 2 infusions. These reactions may result in temporary interruption or withdrawal of treatment [see ADVERSE REACTIONS]. Premedicate with acetaminophen, an antihistamine, and a corticosteroid [see DOSAGE AND ADMINISTRATION]. Infusion reactions may occur despite premedication. Interrupt infusion with ARZERRA for infusion reactions of any severity. Institute medical management for severe infusion reactions including angina or other signs and symptoms of myocardial ischemia [see DOSAGE AND ADMINISTRATION]. If an anaphylactic reaction occurs, immediately and permanently discontinue ARZERRA and initiate appropriate medical treatment. Hepatitis B Virus Reactivation Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, has occurred in patients treated with ARZERRA. Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and also in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive. Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive, and hepatitis B surface antibody [anti-HBs] positive). HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level or detection of HBsAg in a person who was previously HBsAg negative and anti-HBc positive. Reactivation of HBV replication is often followed by hepatitis, i.e., increase in transaminase levels and, in severe cases, increase in bilirubin levels, liver failure, and death. Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with ARZERRA. For patients who show evidence of hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive), consult physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy. Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following treatment with ARZERRA. HBV reactivation has been reported for at least 12 months following completion of therapy. In patients who develop reactivation of HBV while receiving ARZERRA, immediately discontinue ARZERRA and any concomitant chemotherapy, and institute appropriate treatment. Resumption of ARZERRA in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing hepatitis B. Insufficient data exist regarding the safety of resuming ARZERRA in patients who develop HBV reactivation. Hepatitis B Virus Infection Fatal infection due to hepatitis B in patients who have not been previously infected has been observed with ARZERRA. Monitor patients for clinical and laboratory signs of hepatitis. Progressive Multifocal Leukoencephalopathy Progressive multifocal leukoencephalopathy (PML) resulting in death has occurred with ARZERRA. Consider PML in any patient with new onset of or changes in pre-existing neurological signs or symptoms. If PML is suspected, discontinue ARZERRA and initiate evaluation for PML including neurology consultation. Tumor Lysis Syndrome Tumor lysis syndrome (TLS), including the need for hospitalization, has occurred in patients treated with ARZERRA. Patients with high tumor burden and/or high circulating lymphocyte counts ( > 25 x 109/L) are at greater risk for developing TLS. Consider tumor lysis prophylaxis with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion of ARZERRA. For treatment of TLS, administer aggressive intravenous hydration and antihyperuricemic agents, correct electrolyte abnormalities, and monitor renal function. Cytopenias Severe cytopenias, including neutropenia, thrombocytopenia, and anemia, can occur with ARZERRA. Pancytopenia, agranulocytosis, and fatal neutropenic sepsis have occurred in patients who received ARZERRA in combination with chlorambucil. Grade 3 or 4 late-onset neutropenia (onset at least 42 days after last treatment dose) and/or prolonged neutropenia (not resolved between 24 and 42 days after last treatment dose) were reported in patients who received ARZERRA [see ADVERSE REACTIONS]. Monitor complete blood counts at regular intervals during and after conclusion of therapy, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Immunizations The safety of immunization with live viral vaccines during or following administration of ARZERRA has not been studied. Do not administer live viral vaccines to patients who have recently received ARZERRA. The ability to generate an immune response to any vaccine following administration of ARZERRA has not been studied. Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of Fertility No carcinogenicity or mutagenicity studies of ofatumumab have been conducted. In a repeat-dose toxicity study, no tumorigenic or unexpected mitogenic responses were noted in cynomolgus monkeys treated for 7 months with up to 3.5 times the maximum human dose (2,000 mg) of ofatumumab. Effects on male and female fertility have not been evaluated in animal studies. Reproductive And Developmental Toxicology Pregnant cynomolgus monkeys dosed with 0.7 or 3.5 times the maximum human dose (2,000 mg) of ofatumumab weekly during the period of organogenesis (gestation days 20 to 50) had no maternal toxicity or teratogenicity. Both dose levels of ofatumumab depleted circulating B cells in the dams, with signs of initial B cell recovery 50 days after the final dose. Following Caesarean section at gestational day 100, fetuses from ofatumumab-treated dams exhibited decreases in mean peripheral B-cell counts (decreased to approximately 10% of control values), splenic B-cell counts (decreased to approximately 15% to 20% of control values), and spleen weights (decreased by 15% for the low-dose and by 30% for the high-dose group, compared with control values). Fetuses from treated dams exhibiting anti-ofatumumab antibody responses had higher B cell counts and higher spleen weights compared with the fetuses from other treated dams, indicating partial recovery in those animals developing anti-ofatumumab antibodies. When compared with control animals, fetuses from treated dams in both dose groups had a 10% decrease in mean placental weights. A 15% decrease in mean thymus weight compared with the controls was also observed in fetuses from dams treated with 3.5 times the human dose of ofatumumab. The biological significance of decreased placental and thymic weights is unknown. The kinetics of B-lymphocyte recovery and the potential long-term effects of perinatal B-cell depletion in offspring from ofatumumab-treated dams have not been studied in animals. Use In Specific Populations Pregnancy Pregnancy Category C There are no adequate or well-controlled studies of ofatumumab in pregnant women. A reproductive study in pregnant cynomolgus monkeys that received ofatumumab at doses up to 3.5 times the maximum recommended human dose (2,000 mg) of ofatumumab did not demonstrate maternal toxicity or teratogenicity. Ofatumumab crossed the placental barrier, and fetuses exhibited depletion of peripheral B cells and decreased spleen and placental weights. ARZERRA should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. There are no human or animal data on the potential short- and long-term effects of perinatal B-cell depletion in offspring following in utero exposure to ofatumumab. Ofatumumab does not bind normal human tissues other than B lymphocytes. It is not known if binding occurs to unique embryonic or fetal tissue targets. In addition, the kinetics of B-lymphocyte recovery are unknown in offspring with B-cell depletion [see Nonclinical Toxicology]. Nursing Mothers It is not known whether ofatumumab is secreted in human milk; however, human IgG is secreted in human milk. Published data suggest that neonatal and infant consumption of breast milk does not result in substantial absorption of these maternal antibodies into circulation. Because the effects of local gastrointestinal and limited systemic exposure to ofatumumab are unknown, caution should be exercised when ARZERRA is administered to a nursing woman. Pediatric Use Safety and effectiveness of ARZERRA have not been established in children. Geriatric Use In Study 1, 68% of patients (148/217) receiving ARZERRA plus chlorambucil were 65 years and older. Patients age 65 years and older experienced a higher incidence of the following Grade 3 or greater adverse reactions compared with patients younger than 65 years of age: neutropenia (30% versus 17%) and pneumonia (5% versus 1%) [see ADVERSE REACTIONS]. In patients 65 years and older, 29% experienced serious adverse events compared with 13% of patients younger than 65 years. No clinically meaningful differences in the effectiveness of ARZERRA plus chlorambucil were observed between older and younger patients [see Clinical Studies]. In refractory CLL, clinical studies of ARZERRA did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects [see CLINICAL PHARMACOLOGY]. Renal Impairment No formal studies of ARZERRA in patients with renal impairment have been conducted [see CLINICAL PHARMACOLOGY]. Hepatic Impairment No formal studies of ARZERRA in patients with hepatic impairment have been conducted. Last reviewed on RxList: 4/30/2014
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Health Services in

Drug Database Online

Welcome to Women's Health Care an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically Arzerra. Find what medications you are taking today.